
UniQure, the Dutch gene therapy company, said Monday that it had temporarily halted the clinical development of its hemophilia B treatment after a patient was diagnosed with liver cancer.
The clinical hold, mandated by the Food and Drug Administration, encompasses three ongoing studies of Uniqure’s hemophilia B gene therapy called etranacogene dezaparvovec. Patient dosing in all three studies had already been completed and there is no plan to enroll or treat new patients, the company said.